A phase 2 study of vorinostat in acute myeloid leukemia
Élise Schaefer(Pennsylvania State University), S. D. Gore(Johns Hopkins University), K. M. Laumann(Mayo Clinic), Arturo Loaiza‐Bonilla, John F. DiPersio(Washington University in St. Louis), Vivek Roy(Jacksonville College), James L. Slack(Memorial Sloan Kettering Cancer Center), Igor Espinoza‐Delgado(National Institutes of Health), Mark Juckett(University of Wisconsin–Madison), Wenting Wu(East China Normal University)
Cited by 119
Related Papers
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
<i>TP53</i> and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
|New England Journal of Medicine|2016|783